Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antiangiogenesis
A new hypoxia-dependent agent inhibits tumor-specific neovascularization
April 22nd, 2003
A new hypoxia-dependent agent inhibits tumor-specific neovascularization. According to published research from Japan, "tumor angiogenesis is initiated by angiogenic factors that are produced in large amounts by hypoxic tumor cells. The inhibition of this step may lead to tumor-specific antiangiogenesis because normal tissues are not usually hypoxic. On the other hand, blocking a biological function of endothelial cells is known to result in angiogenic inhibition." "To produce a tumor-specific and powerful antiangiogenesis, we determined whether potent angiogenic inhibition could be achieved by inhibiting the production of angiogenic factors by...
Source: Cancer Weekly (2003-04-22)
|
